Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer

The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.

Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study

Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.

Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy

Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.

Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.

bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod

bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.

Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA

Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $65.23 in the latest trading session, marking a +1.94% move from the prior day.

The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences

The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences

Sheraz Mian headshot

Top Stock Reports for UnitedHealth, Sony & American Tower

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Sony (SNE), and American Tower (AMT).

Roche (RHHBY) Stops Dosing in Huntington's Disease Study

Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.

Gilead (GILD) Expands NASH Collaboration With Novo Nordisk

Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.

Gilead Sciences (GILD) Stock Moves -0.53%: What You Should Know

Gilead Sciences (GILD) closed at $64.08 in the latest trading session, marking a -0.53% move from the prior day.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails

Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.

Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $64.75 in the latest trading session, marking a +0.2% move from the prior day.

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study

Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.

Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss

Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.